BRNS - CIK 0001828185
Barinthus Biotherapeutics plc. (BRNS) reported net income of -$66.43M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$66.43M | -8.8% |
| FY 2024 | -$61.07M | +16.7% |
| FY 2023 | -$73.35M | -1473.0% |
| FY 2022 | $5.34M | +110.5% |
| FY 2021 | -$50.87M | -187.3% |
| FY 2020 | -$17.71M | - |
Barinthus Biotherapeutics plc. (BRNS) reported net income of -$66.43M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Barinthus Biotherapeutics plc.'s net income declined from -$17.71M to -$66.43M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.